title: Hyperkalaemia and selective hypoaldosteronism in myotonic dystrophy.
abstract: Myotonic dystrophy (MyD) is a common genetic neuromuscular disorder in which chromosome 19 gives rise to an abnormal expansion of CTG-trinucleotide repeats. MyD is a highly variable multisystem disorder with muscular and nonmuscular abnormalities. Increasingly, endocrine abnormalities, such as gonadal, pancreatic, and adrenal dysfunction are being uncovered. Herein we present three unrelated cases with MyD with abnormally elevated serum potassium; 2 of the 3 cases presented clinically with cardiac dysrhythmias. Hyperkalaemic conditions such as renal failure, cortisol deficiency, pseudohyperkalaemia, and hyperkalaemic periodic paralysis were excluded. Further endocrine evaluation revealed baseline hypoaldosteronism associated with elevated renin activity. Perturbation of the renin-angiotensin-aldosterone system resulted in appropriately enhanced renin activity but with a subnormal aldosterone response, which appeared to be due to adrenal hyporesponsiveness. The treatment of all cases with fludrocortisone was without effect. Whether the apparent mineralocorticoid abnormality in MyD is due to associated hormonal perturbations (i.e. excessive ACTH responsiveness. elevated cytokines, elevated atrial natriuretic hormone, etc.), adrenal atrophy, and/or a manifestation of the underlying kinase dysfunction is uncertain, but merits further evaluation in view of the clinical consequence of hyperkalaemia.
authors.affiliation: Department of Medicine, Section of Endocrinology, VAMC, Washington, DC, USA.
authors.forename: Dolly
authors.initials: D
authors.lastname: Misra
authors.forename: Shari
authors.initials: S
authors.lastname: DeSilva
authors.forename: Herbert
authors.initials: H
authors.lastname: Fellerman
authors.forename: D Robert
authors.initials: DR
authors.lastname: Dufour
authors.forename: David H P
authors.initials: DH
authors.lastname: Streeten
authors.forename: Eric S
authors.initials: ES
authors.lastname: Nylen
mesh_terms: D000302:Adrenal Cortex / Q000503:physiopathology; D000324:Adrenocorticotropic Hormone; D000328:Adult; D004232:Diuretics; D005260:Female; D005438:Fludrocortisone / Q000627:therapeutic use; D005665:Furosemide; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D006947:Hyperkalemia / Q000150:complications* / Q000503:physiopathology; D006994:Hypoaldosteronism / Q000150:complications* / Q000503:physiopathology; D008297:Male; D008901:Mineralocorticoids / Q000627:therapeutic use; D009223:Myotonic Dystrophy / Q000150:complications* / Q000235:genetics / Q000503:physiopathology; D009270:Naloxone; D012083:Renin / Q000097:blood; D013268:Stimulation, Chemical; D017211:Treatment Failure; D019680:Trinucleotide Repeat Expansion
chemical_list: D004232:Diuretics; D008901:Mineralocorticoids; D009270:Naloxone; D005665:Furosemide; D000324:Adrenocorticotropic Hormone; D012083:Renin; D005438:Fludrocortisone; D006854:Hydrocortisone